echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > FDA approves Igalmi for schizophrenia or bipolar disorder

    FDA approves Igalmi for schizophrenia or bipolar disorder

    • Last Update: 2022-05-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, the biopharmaceutical company BioXcel Therapeutics announced that the FDA approved Igalmi for the treatment of schizophrenia or bipolar disorder (type I or II)


    FDA

    Formerly known as manic-depressive disorder, bipolar disorder is a mental health disorder that can cause extreme mood swings, including high moods (mania or hypomania) and low moods (depression)


    Treatment for bipolar disorder includes medications to stabilize mood (mood stabilizers, such as lithium and certain antiseizure medications), antipsychotic medications, some antidepressants, psychotherapy, education, and support


    The drug, expected to launch later this quarter, will be self-administered by patients under the supervision of a healthcare provider


    Patients met the primary endpoints of both studies two hours after receiving Igalmi at doses of 120 μg and 180 μg


    The drug also exhibited rapid onset of action, with the 180 μg dose being significantly different from placebo at 20 minutes in SERENITY I and the 120 μg dose at 30 minutes; and in SERENITY II, Both doses were significantly different from the placebo group at 20 minutes


    BioXcel is also developing Igalmi for the acute treatment of Alzheimer's disease and the adjunctive treatment of major depressive disorder


     

    Original source:

    Original source:

    https://firstwordpharma.


    https://firstwordpharma.
    com/story/5542437 https://firstwordpharma.
    com/story/5542437

    Leave a comment here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.